ArticleAmerican journal of translational research2025
Risk factors and establishment of a nomogram model for pulmonary arterial hypertension complicated by acute exacerbation of chronic obstructive pulmonary disease.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors for pulmonary arterial hypertension (PAH) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and develop a nomogram model to facilitate early clinical identification of high-risk patients and guide personalized treatment plans.
methodsThis retrospective study included 602 AECOPD patients treated at Zhoushan Women and Children's Hospital from June 2018 to May 2023. Patients were divided into two groups based on the presence or absence of PAH. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for AECOPD with PAH. A nomogram model was then established based on these factors. The Bootstrap self-sampling method was used to evaluate the predictive performance of the model. Indicators such as the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and consistency index (C-index) were calculated to evaluate the discrimination and calibration of the model.
resultsAmong 602 AECOPD patients, 8.31% developed PAH. Compared with the non-PAH group, the PAH group exhibited a higher proportion of Chronic Obstructive Lung Disease (GOLD) grade IV, hypertension, and elevated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Multivariate logistic regression analysis identified GOLD grade, hypertension, NLR, PLR, and NT-proBNP as independent risk factors for AECOPD-associated PAH. A nomogram prediction model was developed based on these variables. The model's AUC, sensitivity, and specificity in the training set were 0.906 (95% confidence interval (CI): 0.847-0.966), 0.850, and 0.862, respectively, and those in the validation set were 0.861 (95% CI: 0.715-0.932), 0.700, and 0.948, respectively. The C-index for the calibration curves of the model in both the training and validation sets was high (0.906 and 0.861, respectively). Decision curve analysis indicated a positive net benefit within a certain risk threshold.
conclusionPAH in AECOPD patients was associated with GOLD grade, hypertension, NLR, PLR, and NT-proBNP. The developed nomogram demonstrated strong predictive performance and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.